BIM
SVA

Bogle Investment Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Bogle Investment Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-136,772
Closed -$771K – 473
2014
Q2 		$771K Sell
136,772
-60,285
-31% -$366K 0.05% 251
2014
Q1 		$1.42M Buy
+197,057
New +$1.3M 0.1% 247
2013
Q4 		– Sell
-221,061
Closed -$1.32M – 445
2013
Q3 		$1.32M Buy
+221,061
New +$1.06M 0.13% 203

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bogle Investment Management's SVA Position: Q3 2014 in Review

Bogle Investment Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2014, closing a stake of 136,772 shares — an estimated $771K sold.

Bogle Investment Management first reported a position in SVA in Q3 2013 and held it in 3 quarters. The position peaked at $1.42M in Q1 2014. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • Bogle Investment Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2014 after selling out during the quarter.
  • Bogle Investment Management sold 136,772 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $771K.
  • Bogle Investment Management first reported a position in Sinovac Biotech, Ltd in Q3 2013 and held it in 3 quarters.
  • Bogle Investment Management's Sinovac Biotech, Ltd position peaked at $1.42M in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on Bogle Investment Management's 13F filing for Q3 2014, filed 13 Nov 2014.